Federal health officials lifted a pause on use of the Johnson & Johnson COVID-19 vaccine on Friday following an 11-day review and the recommendation of a panel of experts who determined it met safety standards despite rare instances of severe blood clots.
“We have concluded that the known and potential benefits of the Janssen COVID-19 Vaccine outweigh its known and potential risks in individuals 18 years of age and older,” Acting FDA Commissioner Janet Woodcock said in a statement. “We are confident that this vaccine continues to meet our standards for safety, effectiveness and quality.”
This is a breaking story. Check back for updates.